Mr. Steven Theriault reports

CYTOPHAGE RECEIVES FEDERAL SUPPORT FOR ENTRY INTO EUROPEAN MARKET THROUGH FRANCE BIOMANUFACTURING MISSION

Cytophage Technologies Ltd. will participate in the Canadian biomanufacturing mission held in Lyon and Paris, France, from Sept. 21 to Sept. 25, 2025, under the Canadian International Innovation Program (CIIP). This government-led initiative, organized by Global Affairs Canada and the National Research Council of Canada, brought together leading Canadian companies to explore co-innovation opportunities within the French bioeconomy.

"We engaged with prospective European partners on this mission to help advance the commercialization of our bacteriophage products globally," said Dr. Steven Theriault, chief executive officer of Cytophage. "We were honoured to represent Canadian innovation alongside our esteemed industry peers, and grateful for the federal government's support for this mission. We extend our sincere thanks to the Trade Commissioner Service | Service des delegues commerciaux of Canada and the Canadian International Innovation Program (CIIP) for making this initiative possible."

Participation in this mission allowed Cytophage to showcase its innovative bacteriophage products for human and animal health, most notably at the 10th Bioproduction Congress in Lyon, France, which is Europe's premier biopharmaceutical manufacturing event. The company's participation included one-on-one meetings and numerous networking opportunities aimed at establishing new biomanufacturing partnerships, and accelerating the company's entry into the European Union market. The program also featured high-level visits with French industry leaders, university hospitals and innovation clusters.

Cytophage will advance discussions with leading European animal health companies regarding distribution opportunities for its animal health bacteriophage products following the recent completion of successful pilot studies in Europe (see Sept. 23, 2025, press release). Cytophage will also explore larger-scale R&D (research and development) collaborations identified from meetings during the mission as it works to continue leveraging its proprietary bacteriophage design platform to drive international growth.

The government's inclusion of Cytophage in this mission underscores federal support and recognition for the company's leadership in bacteriophage technology and its potential to address the urgent global challenge of antimicrobial resistance.

About Cytophage Technologies Ltd.

Cytophage Technologies is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization. Bacteriophages are viruses that only infect and kill bacteria. These natural killers of bacteria can overcome cellular or organism-level defences. They are nature's version of antibiotics.

Cytophage is improving bacteria's natural predators with environmental as well as genetic modifications to bring safe and toxin-free killer solutions to large addressable markets with an initial focus on animal health which offers a fast-track to near-term revenue. As a leading bacteriophage manufacturer in Canada and powered by a large library of strains, Cytophage is committed to addressing the global challenge of antibiotic resistance (AMR).

The WHO predicts that AMR will be the leading cause of human mortality by 2050. Many countries have already banned or limited preventative antibiotic use in animal production including 27 European Union countries, United States, Canada, Brazil, Bangladesh, India and Mexico. In addition to that, consumers all over the world are demanding organic and antibiotic-free products.

Cytophage is using a derisked and patented technology to advance innovative and cost-competitive products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health and food security.

We seek Safe Harbor.